Oppenheimer Maintains Outperform on Amrize, Lowers Price Target to $55

Benzinga · 1d ago
Oppenheimer analyst Bryan Blair maintains Amrize (NYSE:AMRZ) with a Outperform and lowers the price target from $62 to $55.